ASCO 2024 | Phase II study of petosemtamab and pembrolizumab for recurrent/metastatic HNSCC
Jerome Fayette, MD, Centre Lèon Bèrard, Lyon, France, shares insight into the results of a Phase II trial (NCT03526835), including patients with PD-L1-positive recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) treated periodically with petosemtamab plus pembrolizumab. The study showed a high response rate at the primary endpoint, with notable partial responses. Efficacy was similar in both human papillomavirus-negative (HPV-) and -positive (HPV+) populations and between low and high expressors of PD-L1 with a CPS scoring of 1-19 (CPS 1-19). Although some patients experienced grades 1-3 toxicity, these side effects were manageable with pre-medication and adjusting the administration rate. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Honoraria – Bristol-Myers Squibb; Hookipa Pharma; Merck Serono; Merck Sharp & Dohme; Roche
Consulting or Advisory Role – Bristol-Myers Squibb; Elevar Therapeutics; Hookipa Pharma; ITeos Therapeutics; Merck Serono; Merck Sharp & Dohme; Seagen
Research Funding – AstraZeneca (Inst); Bristol-Myers Squibb (Inst)
Travel, Accommodations, Expenses – Bristol-Myers Squibb; Merck Sharp & Dohme
